It is possible to manufacture monoclonal antibodies using traditional methods, but the challenges inherent in bispecific antibodies such as low titer, mismatched chains, unwanted fragments and higher aggregation levels require a heightened analytical focus on clonal cell selection. Here, Stuart Jamieson and Alice Harrison at Lonza discuss high-throughput analytical strategies that enable right-first-time selection of the optimal clone to take through to clinical manufacture.
Authors: Stuart Jamieson, Global Technical and CMC Director for Downstream Development; Alice Harrison, Global Technical Director (CMC and Analytics)